SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
____________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): May 4, 2005
SKINVISIBLE,
INC.
(Exact
name of registrant as specified in its charter)
Nevada |
000-25911 |
88-0344219 |
|
(State
or other jurisdiction of
incorporation) |
(Commission
File Number) |
(I.R.S.
Employer
Identification
No.) |
|
6320
S. Sandhill Rd., Suite 10, Las Vegas, Nevada |
89120 |
|
(Address
of principal executive offices) |
(Zip
Code) |
Registrant’s
telephone number, including area code: (702)
433-7154
___________________________________________
(Former
name or former address, if changed since last
report) |
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
[
] |
Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425) |
| |
|
|
[
] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
[
] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
|
|
[
] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
SECTION
1 -- REGISTRANT’S BUSINESS AND OPERATIONS
Item
1.01 Entry
into a Material Definitive Agreement.
On May 4,
2005, we entered into a Distribution Agreement (“Agreement”) with Safe4Hours,
Inc. (“Safe4Hours”), a Nevada corporation. Under the terms of this Agreement, we
granted Safe4Hours the exclusive right to distribute, market, sell, and promote
our antimicrobial hand sanitizer in every country in the whole except Canada,
the United States, and Mexico. The rights to distribute, market, sell, and
promote our antimicrobial hand sanitizer in Canada, the United States, and
Mexico are held by Dermal Defense, Inc., a Michigan corporation. Safe4Hours
acquired these rights for an up-front fee of $1,000,000, of which $25,000 has
been received and the remaining $975,000 is payable in quarterly installments
based upon a predetermined formula until the balance is received, and a royalty
fee of no less than 5% of gross revenue of all sales.
A copy of
the distribution agreement is attached.
SECTION
9 - FINANCIAL STATEMENTS AND EXHIBITS
*
Portions of the exhibit have been omitted pursuant to a request for confidential
treatment.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Skinvisible,
Inc.
/s/
Terry
Howlett
Terry
Howlett, Chief Executive Officer
Date:
May
10, 2005